Shots:
The US FDA has approved Avtozma IV, a biosimilar to Actemra (tocilizumab), for treating cytokine release syndrome in pts (≥2yrs.), covering all Actemra IV-approved indications in the US; expected to be available in the US by Aug 31, 2025
In Jan 2025, the US FDA approved Avtozma IV to treat rheumatoid arthritis (RA), giant…
